Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Uptune programme

    - PMLiVE

    Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug

    Cladribine capsules could become the first ever oral treatment for gMG

    - PMLiVE

    New centre for life sciences launched in London

    Victoria House is a state-of-the-art life sciences hub

    - PMLiVE

    BioNTech announces £1bn UK investment to boost regional R&D presence

    The UK government has also agreed to award the company a grant of up to £129m

    Map Treatment Pathways Virtually – Engaging Your Advisors Creatively

    Optimize product strategy! Discover how virtual profiling can accurately map treatment pathways and pinpoint opportunities for your innovations while engaging your advisors in a creative way!

    Impetus Digital

    - PMLiVE

    Eli Lilly and Creyon Bio enter oligonucleotide therapy partnership worth over $1bn

    The companies will aim to develop RNA-targeted drugs for a broad range of diseases

    - PMLiVE

    Merck KGaA expands rare tumour portfolio with $3.9bn SpringWorks acquisition

    SpringWorks’ Gomekli was approved by the FDA earlier this year to treat patients with NF1

    - PMLiVE

    Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use

    The neurological disorder affects more than 150,000 people in the UK

    Establishing Remote Work Norms – Building Company Culture Virtually

    Ready to redefine remote work in pharma? The second step is establishing clear norms, processes, and expectations that resonate with your team. Dive into our series for more tips on...

    Impetus Digital

    - PMLiVE

    Merck KGaA/Abbisko share positive phase 3 results for pimicotinib in rare tumour type

    The companies entered into a licensing agreement for the candidate in December last year

    - PMLiVE

    UK life sciences sector responds to Labour government’s Autumn Budget

    Key measures include a £520m life sciences innovative manufacturing fund

    - PMLiVE

    Merck KGaA signs definitive agreement to acquire Mirus Bio in deal worth $600m

    The deal aims to advance Merck’s viral vector manufacturing of cell and gene therapies

    - PMLiVE

    Ipsen announces launch of new UK headquarters in London life sciences community

    The Paddington site will serve as one of the company’s three global hubs

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links